Akero Therapeutics Inc (AKRO)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
45.22 +0.56 (+1.25%) 03/21/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 45.22 unch (unch) 16:55 ET
for Fri, Mar 21st, 2025
Try Excel 
Watch
-
Add or delete the symbol from one or more Watchlists.
-
Create New Watchlist
This name already in use.
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 340,238 | 234,207 | 249,773 | 150,483 | 187,242 |
| Marketable Securities | 402,840 | 315,803 | 101,676 | 37,775 | 81,145 |
| TOTAL | $770,380 | $559,962 | $355,173 | $193,582 | $271,345 |
| Non-Current Assets | |||||
| PPE Net | N/A | 18 | 47 | 90 | 131 |
| Investments And Advances | 54,751 | 19,283 | 0 | 0 | 0 |
| Other Non-Current Assets | 755 | 1,008 | 1,350 | 1,876 | 1,863 |
| TOTAL | $55,506 | $20,309 | $1,397 | $1,966 | $1,994 |
| Total Assets | $825,886 | $580,271 | $356,570 | $195,548 | $273,339 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 9,027 | 7,038 | 7,968 | 6,706 | 3,428 |
| Accrued Expenses | 30,727 | 12,090 | 11,115 | 18,422 | 9,683 |
| TOTAL | $39,754 | $19,128 | $19,083 | $25,128 | $13,111 |
| Non-Current Liabilities | |||||
| Long Term Debt | 35,491 | 25,018 | 9,846 | 0 | N/A |
| aiOther Non-Current Liabilities | 529 | 819 | 1,079 | 1,311 | 1,516 |
| TOTAL | $36,020 | $25,837 | $10,925 | $1,311 | $1,516 |
| Total Liabilities | $75,774 | $44,965 | $30,008 | $26,439 | $14,627 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 79,620 | 56,298 | 46,971 | 35,013 | 34,770 |
| Common Shares | 7 | 6 | 5 | 4 | 4 |
| Retained earnings | -826,156 | -574,096 | -422,337 | -310,304 | -209,527 |
| Other shareholders' equity | 948 | 270 | 37 | -27 | -3 |
| TOTAL | $750,112 | $535,306 | $326,562 | $169,109 | $258,712 |
| Total Liabilities And Equity | $825,886 | $580,271 | $356,570 | $195,548 | $273,339 |